AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02292784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
Study NCT02292784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
Study NCT03619811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reflux Band® Upper Esophageal Sphincter (UES) Assist Device
Description: UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
Study NCT00348933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Description: 100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
Study NCT00348933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine
Description: 200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
Study NCT00348933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metafolin
Description: 0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
Study NCT00348933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg by mouth per day for all weights and ages
Study NCT01303003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
Study NCT01303003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
Study NCT02065271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: herbal supplement
Study NCT02065271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo supplement
Study NCT02608333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESDM-12
Description: ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery.
Study NCT02608333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: heteregenous as usual community intervention
Study NCT01991639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and physical activity intervention
Description: Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
Study NCT03188172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy
Study NCT03188172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Chemotherapy
Study NCT03188172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Chemotherapy
Study NCT03188172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Chemotherapy
Study NCT03188172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Chemotherapy
Study NCT03188172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Chemotherapy
Study NCT03188172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Haematopoietic agent for the stem cell harvest
Study NCT04322201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter
Description: Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care
Study NCT04322201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided intermittent large-volume paracentesis
Description: Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter
Study NCT01926327 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection
Description: Injection of PRP in patients with knee osteoarthritis.
Study NCT01926327 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06451731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHOLEXSEM
Description: Phonological, Lexical, and Semantic training
Study NCT06451731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE
Description: See arm description
Study NCT00476567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: standard antenatal care
Study NCT00476567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: specific training program
Description: a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
Study NCT00972140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Formoterol-HFA pMDI 12µg twice daily
Study NCT00972140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol-DPI 12 µg twice daily
Study NCT01659554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75 mg/m2) prepared in 2L normal saline.
Study NCT01659554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
Study NCT01964040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia
Study NCT01964040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia
Study NCT03936296 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mpMR guided MR-US fusion transrectal prostate biopsy
Description: mpMR images will be loaded to US fusion platform and registration of the will be performed. Suspicious lesions on MR which have PIRADS score 3 and above are targeted. Additional 2-4 cores biopsies will be taken them
Study NCT01964040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia
Study NCT01135667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel 150 mg once daily for 30 days
Study NCT03936296 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 12 core standard transrectal prostate biopsy
Description: Under the guidance of transrectal ultrasonography, 12 core biopsies taken from apex, apex lateral, mid, mid lateral, base and base lateral of right and left prostate lobe
Study NCT01135667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 10 mg
Description: Prasugrel 10 mg once daily for 30 days
Study NCT01193296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT01193296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study NCT04517357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+Apatinib
Description: Fluzoparib-Apatinib combination
Study NCT04517357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzoparib
Description: Fluzoparib monotherapy
Study NCT04517357 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluzoparib+Apatinib
Description: Fluzoparib-Apatinib combination
Study NCT03699475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rivogenlecleucel
Description: Biological: T cells transduced with caspase 9 safety switch
Study NCT03699475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimiducid
Description: administered to inactivate rivogenlecleucel in the event of GVHD
Study NCT03699475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: GVHD prophylaxis
Study NCT03699475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haplo-HSCT
Description: treatment for disease
Study NCT03699475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: haplo-HSCT
Description: treatment for disease
Study NCT03243708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk calculator
Description: Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
Study NCT06506370 — intervention group
Intervention type: OTHER
Intervention: nonsurgical periodontal treatment
Description: The patients underwent treatment in accordance with the guidelines of the European Federation of Periodontology (EFP). Initially, patients were informed of their condition, educated on oral hygiene practices, and advised to cease detrimental habits such as smoking. Following this, supragingival cleaning was conducted using ultrasound, with manual subgingival instrumentation utilizing a reduced set of Gracey curettes for pockets exceeding 4 mm with persistent bleeding or greater than 6 mm.
Study NCT01610375 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telephone Follow-up
Description: This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
Study NCT01471431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spontaneous breathing trial
Description: The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).~During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia \<100 for >15 seconds or oxygen saturation by pulse oximetry \<85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met.
Study NCT01955798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic direct entry Trocar
Description: Laparoscopic direct entry with trocar
Study NCT01955798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic entry Veress needle
Description: Laparoscopic entry with Veress needle
Study NCT01955798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trocar
Study NCT01955798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Veress needle
Study NCT00528970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOA-728
Description: MOA-728 will be administered per the dose and schedule specified in the arm.
Study NCT00528970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
Study NCT01440543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water immersion insertion AND CO2 insufflation
Description: * room temperature water infused by water pump into the colon just to facilitate scope insertion~* CO2 insufflation by CO2 insufflation system during colonoscope withdrawal and mucosal inspection
Study NCT01440543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water immersion insertion
Description: * room temperature water infused by water pump into the colon just to facilitate scope insertion~* standard room air insufflation during colonoscope withdrawal and mucosal inspection
Study NCT01440543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Description: - CO2 insufflation by CO2 insufflation system during both colonoscope insertion and withdrawal
Study NCT03932006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fengshigutong Capsule plus Imrecoxib
Description: Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
Study NCT03932006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fengshigutong Capsule
Description: Fengshigutong Capsule 1.2g twice a day,orally
Study NCT03932006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imrecoxib
Description: Imrecoxib 0.1g twice a day,orally
Study NCT04710771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Lying Position
Description: patient lies on his/ her stomach facing floor.
Study NCT04710771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone Lying Position
Description: patient lies on his/ her stomach facing floor.
Study NCT04710771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alternate nostril breathing
Description: patient inspires with one nostril at a time, right or left one by one and expires by mouth.
Study NCT04671953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study NCT04671953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Specified dose on specified days
Study NCT04280770 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 23 PARS PLANA VITRECTOMY
Description: We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
Study NCT04280770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 23 PARS PLANA VITRECTOMY
Description: We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
Study NCT01143233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control formula
Description: infants are fed a commercial hydrolyzed formula
Study NCT01918254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV infusion will be administered as per schedule described in individual arm.
Study NCT01143233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention formula 1
Description: formula has hydrolysed protein and a different protein content
Study NCT01143233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention formula 2
Description: formula has hydrolysed protein, different protein content and pro- and prebiotics
Study NCT01143233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention formula 3
Description: formula has hydrolysed protein, different protein content and pro- and prebiotics
Study NCT01918254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab IV infusion will be administered as per schedule described in individual arm.
Study NCT01918254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumretuzumab
Description: Lumretuzumab will be administered as per schedule described in individual arm.
Study NCT01816503 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
Study NCT03571945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-spectral Index (BIS QUATRO REF #186-0106)
Description: GA will be monitored and controlled with Bi-spectral index (BIS).
Study NCT03571945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: End tidal anaesthesia gas concentration (ETAG)
Description: GA will be monitored and controlled with end-tidal anaesthesia gas concentration
Study NCT01596556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: both groups will be given nicotine lozenges before a VO2 test and a HTT.
Study NCT01596556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: both groups will be given nicotine lozenges before a VO2 test and a HTT.
Study NCT01596556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cigarette smoking
Description: the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
Study NCT00541190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA
Description: Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
Study NCT03611842 — intervention group
Intervention type: OTHER
Intervention: preservation of mucosal otitis media
Description: Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum
Study NCT03787979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic stiffening technique
Description: Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.
Study NCT03787979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic stiffening technique
Description: Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.
Study NCT03787979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic relaxing technique
Description: Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.